Remedy Plan Therapeutics
Gaithersburg
About Remedy Plan Therapeutics
Remedy Plan Therapeutics is a pre-clinical-stage company developing small molecule therapeutics to halt tumor growth and disrupt the cancer stem cells that cause metastasis. Our approach is to develop effective, non-toxic treatments that target the dangerous embryonic properties of cancer stem cells, which form the basis for cancer growth, spread, and resistance to chemotherapy. Remedy Plan is positioned to deliver one first-in-class drug candidate for Phase I clinical development approximately 15 months after Series A funding Remedy Plan's proprietary drug screening platform identifies drug candidates that differentiate cancer stem cells, disrupt proliferation, and inhibit formation of new tumors. From the initial screen of 40,000 drug components, a lead candidate is currently undergoing optimization and mechanism of action studies in preparation for Phase I clinical trials. With the second screen of over 100,000 drug components completed, Remedy Plan aims to have at least two drugs in clinical development by 2020.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $47.2M
- Last round: Series Unknown (May 2025)
- Website: remedyplan.com
- Phone: 240-408-4854
Industries & Categories
Biotechnology, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/remedy-plan-therapeutics-99636 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.